MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
PSEC
Prospect Capital Corporation
There isn't enough reported data to score PSEC yet.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
PSEC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| N/A | |
| N/A |
PSEC's profitability is currently stable, but its revenue is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like PSEC.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
PSEC PE Valuation
PSEC has no meaningful PE right now: it lost money over the past year.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over PSEC on the outlook, with more favorable earnings and revenue expectations.
PSEC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong decline | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect PSEC's earnings and revenue to decline, with profitability weakening.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the stronger earnings trend. Trailing diluted EPS is up 29% for MS versus PSEC down 505%.
PSEC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.32 | — |
| Q3 2025 | -$0.89 | -$0.67 |
| Q2 2025 | -$1.35 | -497% |
| Q1 2023 | -$0.51 | -124% |
| Q4 2022 | $0.14 | -94% |
| Q3 2022 | $0.62 | -76% |
| Q2 2022 | $1.41 | -44% |
| Q1 2022 | $2.14 | -7.8% |
| Q4 2021 | $2.39 | +103% |
PSEC lost $0.89 per share over the past year, a bigger loss than the year before.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the stronger quarterly revenue trend. Revenue is up 12% for MS versus down 104% for PSEC.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
PSEC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $203.3M | -32% |
| Q4 2021 | $293.9M | -17% |
| Q3 2021 | $253.7M | +19% |
| Q2 2021 | $284.3M | +37% |
| Q4 2020 | $353.2M | +753% |
PSEC's revenue has slid since its 2020 peak: −$11M last quarter, down 104% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | 81% | -1.9 points |
| Q4 2021 | 86% | -0.3 points |
| Q3 2021 | 84% | +4.6 points |
| Q2 2021 | 86% | +7.2 points |
| Q1 2021 | 83% | N/A |
| Q4 2020 | 87% | +114 points |
| Q3 2020 | 79% | N/A |
| Q2 2020 | 79% | N/A |
PSEC's operating margin was 81% last quarter, down 1.9 points from the same quarter a year ago.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
PSEC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $381.7M | +37% |
| Q2 2026 | -$43.9M | -$36.3M |
| Q1 2026 | $195.7M | +149% |
| Q4 2025 | $85.6M | -69% |
| Q3 2025 | $279M | +61% |
| Q2 2025 | -$7.6M | -106% |
| Q1 2025 | $78.6M | +$100.8M |
| Q4 2024 | $278.5M | +251% |
PSEC has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over PSEC on shareholder dilution, with a more favorable share count trend.
PSEC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -44% | -405M shares |
| 1 year | +18% | +81M shares |
| 3 years | -4.2% | -22.9M shares |
| 5 years | +37% | +143M shares |
| Available history | +43% | +157M shares |
PSEC has 524M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
PSEC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | 4.7x | High |
| Q1 2022 | 2.9x | Moderate |
| Q4 2021 | 2.4x | Moderate |
| Q3 2021 | 2.0x | Moderate |
| Q2 2021 | 2.3x | Moderate |
| Q1 2021 | 2.3x | Moderate |
| Q4 2020 | 4.6x | High |
| Q3 2020 | 16.0x | High |
PSEC's net debt is about 4.7 years of its operating earnings (EBITDA), up from 2.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like PSEC.
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
PSEC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 13.6 | Oversold |
PSEC's weekly RSI is 26 (oversold) and its Stochastic is 14 (oversold).
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
PSEC PE vs Financial Services Sector
| Metric | PSEC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
PSEC has no meaningful PE right now: it lost money over the past year.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over PSEC on trend strength, trading above more of its moving averages.
PSEC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.68 | 16% below |
| 20 week MA | $2.01 | 30% below |
| 50 week MA | $2.36 | 40% below |
| 100 week MA | $2.91 | 52% below |
| 200 week MA | $4.40 | 68% below |
PSEC is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over PSEC on returns for 2026, with the stronger performance.
PSEC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.51 | $5.46 | -16% |
| 2021 | $5.46 | $8.43 | +54% |
| 2022 | $8.43 | $7.16 | -15% |
| 2023 | $7.16 | $5.99 | -16% |
| 2024 | $5.99 | $4.26 | -29% |
| 2025 | $4.26 | $2.51 | -41% |
| 2026 YTD | $2.51 | $1.41 | -44% |
PSEC has finished four years in a row lower, and it's down 44% so far in 2026.